Payment overview · 2025
General Payments
$1,095.73
58 reported records · 18 companies
Healthcare provider profile · identity verified
Robert Neil Honea, MD
Allopathic & Osteopathic Physicians|Family Medicine · REFORM, AL · NPI 1083713556
Verified facts
What the public records show
CMS Open Payments records show Robert Neil Honea, MD received $1,095.73 in general payments during 2025 across 58 reported records.
ABBVIE INC. accounted for 22.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 28 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Linzess, Mounjaro, Ozempic, Rexulti, Shingrix.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Lumigan by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 136 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 136 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 150 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 120 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $247.21 | 22.6% | 15 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $102.05 | 9.3% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $100.32 | 9.2% | 5 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $91.52 | 8.3% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $84.07 | 7.7% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $81.91 | 7.5% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $74.07 | 6.8% | 4 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $64.04 | 5.8% | 3 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $56.87 | 5.2% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $37.69 | 3.4% | 2 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $25.16 | 2.3% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $24.06 | 2.2% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $22.88 | 2.1% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $18.97 | 1.7% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.30 | 1.7% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $15.81 | 1.4% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $15.72 | 1.4% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $15.08 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,095.73 | 58 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $149.09 | 10 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $102.05 | 4 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $100.32 | 5 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $91.52 | 4 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $84.07 | 5 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $81.91 | 5 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $81.91 | 5 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $75.65 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $75.65 | 3 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $64.04 | 3 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $56.87 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $43.17 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $37.69 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $30.90 | 2 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $25.16 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $24.17 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $24.06 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $22.88 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $22.47 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $22.47 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $18.97 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $18.97 | 1 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $18.30 | 1 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $17.15 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $15.81 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $15.72 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $15.72 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $15.08 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| LINZESS linzess |
2025 | Linzess | 2024 | 53 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 150 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 86 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 41 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
53 | 19 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
136 | 26 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
41 | 36 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
43 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
136 | 26 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
150 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
86 | 13 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
55 | 55 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
120 | 23 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 711 | 114 |
| Atorvastatin Calcium | Atorvastatin Calcium | 653 | 173 |
| Montelukast Sodium | Montelukast Sodium | 492 | 131 |
| Pantoprazole Sodium | Pantoprazole Sodium | 482 | 119 |
| Gabapentin | Gabapentin | 475 | 98 |
| Levothyroxine Sodium | Levothyroxine Sodium | 466 | 107 |
| Amlodipine Besylate | Amlodipine Besylate | 371 | 105 |
| Fluticasone Propionate | Fluticasone Propionate | 367 | 106 |
| Omeprazole | Omeprazole | 366 | 107 |
| Metformin Hcl | Metformin Hcl | 320 | 82 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 305 | 84 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 286 | 83 |
| Furosemide | Furosemide | 279 | 80 |
| Tramadol Hcl | Tramadol Hcl | 270 | 56 |
| Potassium Chloride | Potassium Chloride | 268 | 83 |
| Losartan Potassium | Losartan Potassium | 263 | 62 |
| Hydrochlorothiazide | Hydrochlorothiazide | 252 | 74 |
| Diclofenac Sodium | Diclofenac Sodium | 225 | 58 |
| Fenofibrate | Fenofibrate Nanocrystallized | 218 | 53 |
| Meloxicam | Meloxicam | 216 | 56 |
| Carvedilol | Carvedilol | 210 | 55 |
| Famotidine | Famotidine | 210 | 64 |
| Allopurinol | Allopurinol | 204 | 52 |
| Buspirone Hcl | Buspirone Hcl | 197 | 48 |
| Alprazolam | Alprazolam | 192 | 33 |
| Hydralazine Hcl | Hydralazine Hcl | 180 | 42 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 180 | 27 |
| Glimepiride | Glimepiride | 179 | 46 |
| Promethazine Hcl | Promethazine Hcl | 178 | 34 |
| Pravastatin Sodium | Pravastatin Sodium | 176 | 47 |
| Clonazepam | Clonazepam | 169 | 26 |
| Lisinopril | Lisinopril | 169 | 47 |
| Escitalopram Oxalate | Escitalopram Oxalate | 164 | 39 |
| Trazodone Hcl | Trazodone Hcl | 164 | 47 |
| Valsartan | Valsartan | 160 | 32 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 154 | 40 |
| Fluconazole | Fluconazole | 152 | 78 |
| Mounjaro | Tirzepatide | 150 | 23 |
| Metoprolol Succinate | Metoprolol Succinate | 148 | 43 |
| Jardiance | Empagliflozin | 136 | 26 |
| Levofloxacin | Levofloxacin | 135 | 88 |
| Tamsulosin Hcl | Tamsulosin Hcl | 135 | 32 |
| Pregabalin | Pregabalin | 133 | 33 |
| Ibandronate Sodium | Ibandronate Sodium | 128 | 42 |
| Tradjenta | Linagliptin | 125 | 19 |
| Alendronate Sodium | Alendronate Sodium | 124 | 22 |
| Simvastatin | Simvastatin | 122 | 40 |
| Eliquis | Apixaban | 120 | 23 |
| Zolpidem Tartrate | Zolpidem Tartrate | 120 | 22 |
| Prednisone | Prednisone | 119 | 65 |
| Baclofen | Baclofen | 113 | 30 |
| Sertraline Hcl | Sertraline Hcl | 113 | 35 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 112 | 30 |
| Spironolactone | Spironolactone | 109 | 32 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 108 | 26 |
| Atenolol | Atenolol | 107 | 28 |
| Clopidogrel | Clopidogrel Bisulfate | 101 | 28 |
| Ondansetron Hcl | Ondansetron Hcl | 100 | 22 |
| Januvia | Sitagliptin Phosphate | 96 | 21 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 94 | 23 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 94 | 41 |
| Lovastatin | Lovastatin | 90 | 23 |
| Amoxicillin | Amoxicillin | 89 | 62 |
| Doxycycline Hyclate | Doxycycline Hyclate | 89 | 63 |
| Metoprolol Tartrate | Metoprolol Tartrate | 89 | 26 |
| Ozempic | Semaglutide | 86 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 84 | 68 |
| Duloxetine Hcl | Duloxetine Hcl | 83 | 25 |
| Ezetimibe | Ezetimibe | 83 | 21 |
| Clonidine Hcl | Clonidine Hcl | 81 | 26 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 81 | 19 |
| Mirtazapine | Mirtazapine | 75 | 19 |
| Ibuprofen | Ibuprofen | 74 | 15 |
| Methocarbamol | Methocarbamol | 74 | 22 |
| Mometasone Furoate | Mometasone Furoate | 73 | 33 |
| Sucralfate | Sucralfate | 73 | 17 |
| Azithromycin | Azithromycin | 71 | 51 |
| Cephalexin | Cephalexin | 70 | 55 |
| Xarelto | Rivaroxaban | 70 | 12 |
| Naproxen | Naproxen | 69 | 20 |
| Ropinirole Hcl | Ropinirole Hcl | 69 | 16 |
| Nystatin | Nystatin | 68 | 45 |
| Amitriptyline Hcl | Amitriptyline Hcl | 67 | 18 |
| Celecoxib | Celecoxib | 66 | 19 |
| Clindamycin Hcl | Clindamycin Hcl | 66 | 44 |
| Meclizine Hcl | Meclizine Hcl | 66 | 31 |
| Mupirocin | Mupirocin | 65 | 37 |
| Myrbetriq | Mirabegron | 64 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 64 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 64 | 16 |
| Lorazepam | Lorazepam | 63 | 11 |
| Febuxostat | Febuxostat | 58 | 17 |
| Fluoxetine Hcl | Fluoxetine Hcl | 57 | 17 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 55 | 55 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 54 | 39 |
| Colchicine | Colchicine | 53 | 27 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 53 | 18 |
| Linzess | Linaclotide | 53 | 19 |
| Ondansetron Odt | Ondansetron | 53 | 27 |
| Glipizide | Glipizide | 51 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 50 | 15 |
| Methylprednisolone | Methylprednisolone | 49 | 44 |
| Quetiapine Fumarate | Quetiapine Fumarate | 47 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 47 | 13 |
| Ventolin Hfa | Albuterol Sulfate | 47 | 12 |
| Azelastine Hcl | Azelastine Hcl | 46 | 17 |
| Risperidone | Risperidone | 45 | 14 |
| Topiramate | Topiramate | 45 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 44 | 12 |
| Megestrol Acetate | Megestrol Acetate | 44 | 12 |
| Repatha Sureclick | Evolocumab | 44 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 43 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 43 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 42 | 31 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 41 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 41 | 36 |
| Metformin Hcl Er | Metformin Hcl | 40 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 39 | suppressed |
| Estradiol | Estradiol | 39 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 38 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 38 | suppressed |
| Memantine Hcl | Memantine Hcl | 36 | 12 |
| Temazepam | Temazepam | 36 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 35 | suppressed |
| Torsemide | Torsemide | 35 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 33 | suppressed |
| Ketoconazole | Ketoconazole | 33 | 18 |
| Trulicity | Dulaglutide | 33 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 33 | 11 |
| Bumetanide | Bumetanide | 32 | 11 |
| Warfarin Sodium | Warfarin Sodium | 32 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 31 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 31 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 30 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 29 | suppressed |
| Metronidazole | Metronidazole | 29 | 22 |
| Fenofibrate | Fenofibrate | 28 | suppressed |
| Fentanyl | Fentanyl | 28 | suppressed |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 28 | 26 |
| Farxiga | Dapagliflozin Propanediol | 27 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 26 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 26 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 26 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 26 | suppressed |
| Acyclovir | Acyclovir | 25 | suppressed |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 25 | 25 |
| Cefdinir | Cefdinir | 25 | 19 |
| Lactulose | Lactulose | 25 | 15 |
| Bupropion Xl | Bupropion Hcl | 24 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 24 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 24 | suppressed |
| Nabumetone | Nabumetone | 24 | suppressed |
| Nifedipine Er | Nifedipine | 24 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 23 | suppressed |
| Ibu | Ibuprofen | 23 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 22 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 22 | suppressed |
| Klor-Con 10 | Potassium Chloride | 22 | suppressed |
| Lansoprazole | Lansoprazole | 22 | suppressed |
| Sodium Polystyrene Sulfonate | Sodium Polystyrene Sulfonate | 22 | suppressed |
| Verapamil Er | Verapamil Hcl | 22 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 21 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 21 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 21 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 21 | suppressed |
| Finasteride | Finasteride | 21 | suppressed |
| Gemfibrozil | Gemfibrozil | 21 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 20 | suppressed |
| Entresto | Sacubitril/Valsartan | 20 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 20 | suppressed |
| Constulose | Lactulose | 19 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 19 | suppressed |
| Glipizide Er | Glipizide | 19 | suppressed |
| Irbesartan | Irbesartan | 19 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 19 | suppressed |
| Metolazone | Metolazone | 19 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 19 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 19 | 13 |
| Terbinafine Hcl | Terbinafine Hcl | 19 | suppressed |
| Diazepam | Diazepam | 18 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 18 | suppressed |
| Nitroglycerin | Nitroglycerin | 18 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 18 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 17 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 16 | suppressed |
| Klor-Con M20 | Potassium Chloride | 16 | suppressed |
| Levetiracetam | Levetiracetam | 16 | suppressed |
| Lidocaine | Lidocaine | 16 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 16 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 16 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 15 | suppressed |
| Dexamethasone | Dexamethasone | 15 | 11 |
| Metoclopramide Hcl | Metoclopramide Hcl | 15 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 15 | suppressed |
| Olanzapine | Olanzapine | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 15 | suppressed |
| Trulance | Plecanatide | 15 | suppressed |
| Lumigan | Bimatoprost | 14 | suppressed |
| Methimazole | Methimazole | 14 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 14 | suppressed |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Np Thyroid | Thyroid,pork | 14 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 13 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Felodipine Er | Felodipine | 13 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 13 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 13 | suppressed |
| Ranolazine Er | Ranolazine | 13 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 12 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 12 | suppressed |
| Minoxidil | Minoxidil | 12 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 12 | suppressed |
| Darifenacin Er | Darifenacin Hydrobromide | 11 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 11 | suppressed |
| Dutasteride | Dutasteride | 11 | suppressed |
| Glyburide | Glyburide | 11 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Lubiprostone | Lubiprostone | 11 | suppressed |
| Novolin R | Insulin Regular, Human | 11 | suppressed |
| Rexulti | Brexpiprazole | 11 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,095.73 · 58 records | ABBVIE INC. | ACCRUFER, AREXVY, Auvelity, BEXSERO, CAPLYTA, CREON, Cologuard Collection Kit, FANAPT, GEMTESA, INGREZZA, JOURNAVX, Kerendia, LEQVIO, LINZESS, MOUNJARO, NURTEC ODT, OFEV, Ozempic, QULIPTA, REXULTI, Rybelsus, SHINGRIX, SUBLOCADE, UBRELVY, VRAYLAR, Wegovy, ZAVZPRET, ZEPBOUND | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Linzess play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error